Dr. Trojanowski obtained his MD/PhD in 1976 from Tufts University in Boston. After a medicine internship at Mt. Auburn Hospital and Harvard Medical School, he began pathology/neuropathology training at Massachusetts General Hospital and Harvard Medical School from 1977-1979. Dr. Trojanowski completed his training at the University of Pennsylvania in 1980 where he was appointed assistant professor of Pathology and Laboratory Medicine in 1981 and rose to tenured full professor in 1990. Dr. Trojanowski has held, and continues to hold, major leadership positions at the University of Pennsylvania, including but not limited to:

Dr. Jason Karlawish is a Professor of Medicine, Medical Ethics and Health Policy at the University of Pennsylvania Perelman School of Medicine. He is board-certified in geriatric medicine.

Dr. Karlawish is a Senior Fellow of the Leonard Davis Institute of Health Economics, a fellow of the University of Pennsylvania’s Institute on Aging, Director of the Penn Neurodegenerative Disease Ethics and Policy Program, associate director of the Clinical Core and co-associate director of the Alzheimer’s Disease Core Center, and acting co-director of the Penn Memory Center. He is also Director of the Alzheimer’s Disease Center’s Outreach, Recruitment and Education Core. In addition, he directs the Penn Prevention Research Center’s Healthy Brain Research Center, a member of the CDC supported Healthy BRAIN Network dedicated to surveillance, education, awareness and empowerment that promotes brain health.

He is also the project leader of makingsenseofalzheimers.org, a creative space for understanding the past, present and future of Alzheimer’s disease. Produced by the Penn Neurodegenerative Disease Ethics and Policy program and the Outreach, Recruitment and Education Core of the Alzheimer’s Disease Center at the University of Pennsylvania; and made possible by a startup grant from MetLife Foundation, the website launched in September 2014. Making Sense of Alzheimer’s is an evolving forum for conversation about the disease. Its collection of ideas captures the many dimensions of Alzheimer’s, through the perspective of caregivers, patients, artists, researchers and clinicians. Utilizing multi-media formats such as slideshows, video, and audio clips, along with written stories, the site explores the changing understanding of what Alzheimer’s is and how it affects our ethics and ideas of personhood.

His research focuses on neuroethics and policy. He has investigated issues in dementia drug development, informed consent, quality of life, research and treatment decision-making, and voting by persons with dementia. To learn more about his research and scholarship, visit www.jasonkarlawish.com.

Dr. David Wolk is an Assistant Professor of Neurology in the Cognitive Neurology Division of the University of Pennsylvania Perelman School of Medicine. He is board-certified in Neurology.

Dr. Wolk is the director of the Clinical Core and co-associate director of the Alzheimer’s Disease Core Center and is acting co-director of the Penn Memory Center. He completed his medical training at Johns Hopkins University, a Neurology residency at the University of Pennsylvania, and clinical Fellowship training in Cognitive and Behavioral Neurology at Brigham and Women’s Hospital/Harvard Medical School. He also completed a post-doctoral research fellowship studying memory in Alzheimer’s Disease there. Prior to his return to Penn, he was an Assistant Professor at the University of Pittsburgh and their Alzheimer’s Disease Research Center.

Dr. Wolk’s research has focused on memory measures and other markers that allow for early detection of Alzheimer’s disease (AD). One of the major challenges in the diagnosis of very early Alzheimer’s disease is differentiating the memory failures associated with the normal aging process from those reflecting early AD pathology. As such, his research currently focuses on memory changes in healthy aging, Mild Cognitive Impairment, and AD using Event-Related Potentials (a form of EEG), MRI (including structural and functional measures), and novel psychometric testing. It is hoped that these methods will contribute to early detection and intervention with emerging treatment modalities.